C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
A total of 52 intraductal carcinomas were classified according to nuclear size and histologic subtype and immunostained for neuron-specific enolase (NSE) and c-erbB-2 oncoprotein. Eleven out of 13 cases of the large cell comedo variant of intraductal carcinoma exhibited strong c-erbB-2 protein immunoreactivity, while only one was NSE positive. Nineteen out of 23 intraductal carcinomas of small cell type exhibited NSE immunoreactivity. None of these was c-erbB-2 protein positive. Some 72% of NSE positive cases were also immunoreactive for other neuroendocrine screening markers and/or hormones. We conclude that there is an inverse relationship between NSE immunoreactivity and c-erbB-2 protein expression in intraductal carcinomas.
Lilleng
R
R
Department of Pathology, Norwegian Radium Hospital, Oslo, Norway.
Hagmar
B M
BM
Nesland
J M
JM
D001943:Breast Neoplasms / Q000737:chemistry* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000737:chemistry* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D009490:Neurosecretory Systems / Q000166:cytology / Q000502:physiology; D010751:Phosphopyruvate Hydratase / Q000032:analysis*; D011518:Proto-Oncogene Proteins / Q000032:analysis*; D018719:Erb-b2 Receptor Tyrosine Kinases
D010751:Phosphopyruvate Hydratase; D011518:Proto-Oncogene Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases